TTNP
$1.70
Titan Pharma
$.01
.59%
TTNP
Earnings Whisper ®
N/A
1st Quarter March 2019
Consensus:  $0.00
Revenue:  N/A
Monday
Jul 1
4:30 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TTNP reports earnings?
Beat
Meet
Miss

Where is TTNP's stock price going from here?
Up
Flat
Down
Stock chart of TTNP
Analysts
Summary of analysts' recommendations for TTNP
Score
Grade
Pivots
Resistance
$1.75
$1.72
$1.71

$1.68

Support
$1.67
$1.64
$1.63
Tweet
Growth
Description
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Peers
BiogenGilead SciencesAmgenBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsRepligenSangamo Therapeutics